Citius Pharmaceuticals Inc. (CTXR)
$0.60
$-0.03
(-5.20%)
As on 28-Aug-2026 12:33EDT
Market cap
$16 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.2
-
Face value
--
-
Shares outstanding
27,452,570
10 Years Aggregate
CFO
$-138.80 Mln
EBITDA
$-158.57 Mln
Net Profit
$-157.95 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Citius Pharmaceuticals (CTXR)
| -23.3 | 15.4 | -13.6 | -56.5 | -70.9 | -59.5 | -46.3 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Citius Pharmaceuticals (CTXR)
| -80.6 | -78.6 | -4.2 | -48.7 | 51.0 | 0.0 | -1.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Citius Pharmaceuticals (CTXR)
|
0.6 | 16.5 | 7.1 | -49.3 | -881.0 | -55.3 | -- | 0.2 |
| 84.2 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 246.6 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.4 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 104.8 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 349.1 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 529.8 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.... The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Read more
-
Co-Founder, CEO, Chairman & Secretary
Mr. Leonard L. Mazur
-
Co-Founder, CEO, Chairman & Secretary
Mr. Leonard L. Mazur
-
Headquarters
Cranford, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Citius Pharmaceuticals (CTXR)
What is the current share price of Citius Pharmaceuticals Inc (CTXR) Today?
The share price of Citius Pharmaceuticals Inc (CTXR) is $0.60 (NASDAQ) as of 28-Aug-2026 12:33 EDT. Citius Pharmaceuticals Inc (CTXR) has given a return of -70.9% in the last 3 years.
What is the current PB & PE ratio of Citius Pharmaceuticals Inc (CTXR)?
Since, TTM earnings of Citius Pharmaceuticals Inc (CTXR) is negative, P/E ratio is not available.
The P/B ratio of Citius Pharmaceuticals Inc (CTXR) is 0.25 times as on 21-Aug-2026, a 95 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.60 |
0.33 |
2024 |
-0.15 |
0.08 |
2023 |
-0.22 |
0.08 |
2022 |
-5.26 |
1.72 |
2021 |
-0.86 |
0.15 |
What is the 52 Week High and Low of Citius Pharmaceuticals Inc (CTXR)?
The 52-week high and low of Citius Pharmaceuticals Inc (CTXR) are Rs 2.19 and Rs 0.47 as of 28-Aug-2026.
What is the market cap of Citius Pharmaceuticals Inc (CTXR)?
Citius Pharmaceuticals Inc (CTXR) has a market capitalisation of $ 16 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Citius Pharmaceuticals Inc (CTXR)?
Before investing in Citius Pharmaceuticals Inc (CTXR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.